Virpax Pharmaceuticals Inc (VRPX) Financials
Newest figures come from the 10-K for FY2024, filed Mar 3, 2025. Each column of the statement tables below links to the filing it was taken from.
This page shows Virpax Pharmaceuticals Inc (VRPX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Virpax Pharmaceuticals Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Not reported for Q4 2024.
Not reported for Q4 2024.
Not reported for Q4 2024.
Cash & Balance Sheet
Virpax Pharmaceuticals Inc held $1.5M in cash as of Q4 2024; long-term debt is not reported for that period.
Not reported for Q4 2024.
Not reported for Q4 2024.
Margins & Returns
None of these metrics is reported for Q4 2024.
Capital Allocation
None of these metrics is reported for Q4 2024.
VRPX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $1.1M-23.6% | $2.0M+51.5% | $1.6M+30.6% | N/A | $1.5M-46.7% | $1.3M-60.4% | $1.2M-63.0% |
| SG&A Expenses | N/A | $781K-83.1% | $1.5M-22.9% | $1.7M+306.6% | N/A | $4.6M-5.9% | $1.9M-26.3% | $415K-76.7% |
| Operating Income | N/A | N/A | -$3.5M-6.8% | -$3.3M-100.0% | N/A | -$6.1M+20.7% | -$3.2M+45.1% | -$1.7M+67.8% |
| Interest Expense | N/A | $93K | $11K | N/A | N/A | $0 | N/A | N/A |
| Net Income | N/A | N/A | -$3.5M-10.8% | -$3.2M-111.8% | N/A | -$6.0M+21.6% | -$3.1M+47.1% | -$1.5M+70.4% |
| EPS (Basic) | $0.50+112.8% | -$0.43+91.6% | -$1.75+34.2% | -$2.75-111.5% | -$3.90+76.9% | -$5.12-687.7% | -$2.66-432.0% | -$1.30-195.5% |
| EPS (Diluted) | $0.50 | -$0.43 | -$1.75 | -$2.75 | -$3.90 | -$5.12 | -$2.66 | -$1.30 |
| Diluted Shares (Avg) | N/A | 5M | 2M | 1M | N/A | 1M | 1M | 1M |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
VRPX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.6M-83.8% | $304K-97.7% | $2.6M-83.8% | $3.1M-83.1% | $9.6M-51.1% | $13.0M-44.8% | $16.0M-45.7% | $18.5M-46.8% |
| Current Assets | $1.6M-83.8% | $304K-97.7% | $2.6M-83.8% | $3.1M-83.1% | $9.6M-51.1% | $13.0M-44.8% | $16.0M-45.7% | $18.5M-46.8% |
| Cash & Equivalents | $1.5M-83.4% | $17K-99.9% | $1.9M-87.4% | $1.9M-89.0% | $9.1M-51.9% | $12.2M-40.9% | $14.8M-43.2% | $17.0M-44.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.5M-67.9% | $2.4M-63.9% | $5.4M+47.7% | $4.3M+31.9% | $7.7M+148.6% | $6.5M+55.3% | $3.6M+46.8% | $3.3M+50.6% |
| Current Liabilities | $2.5M-67.9% | $2.4M-63.9% | $5.4M+47.7% | $4.3M+31.9% | $7.7M+148.6% | $6.5M+55.3% | $3.6M+46.8% | $3.3M+50.6% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Equity | -$914K-147.2% | -$2.1M-131.5% | -$2.8M-122.7% | -$1.2M-108.0% | $1.9M-88.3% | $6.5M-66.5% | $12.3M-54.3% | $15.2M-53.3% |
| Retained Earnings | -$71.6M-20.3% | -$68.2M-24.1% | -$66.2M-35.2% | -$62.8M-36.8% | -$59.5M-34.2% | -$55.0M-32.9% | -$49.0M-45.3% | -$45.9M-64.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
VRPX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M+4.7% | N/A | -$1.6M+24.7% | -$7.7M-284.9% | -$3.0M-92.1% | -$2.7M+51.8% | -$2.2M+53.9% | -$2.0M+66.8% |
| Stock-Based Compensation | N/A | -$18K-109.1% | $73K-66.8% | $73K-48.3% | N/A | $196K+29.8% | $218K-10.8% | $141K-33.5% |
| Financing Cash Flow | $4.4M | N/A | $1.6M | $454K | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.
VRPX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q | Q2'2310-Q | Q1'2310-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | N/A | N/A | N/A | N/A | -92.1%-52.8pp | -25.3%-3.4pp | -10.0%+5.8pp |
| Return on Assets | N/A | N/A | -133.2%-113.7pp | -102.9%-94.7pp | N/A | -46.0%-13.7pp | -19.5%+0.5pp | -8.2%+6.6pp |
| Current Ratio | 0.63-0.6x | 0.13-1.9x | 0.48-3.9x | 0.72-4.9x | 1.25-5.1x | 2.00-3.6x | 4.37-7.5x | 5.61-10.3x |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 3.98+3.8x | 1.00+0.8x | 0.30+0.2x | 0.22+0.1x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$914K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.63), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Virpax Pharmaceuticals Inc VRPX | FY2024 | N/A | N/A | N/A | N/A | — |
| Scopus Biopharma Inc. SCPS | FY2022 | $0 | N/A | N/A | $13K | — |
| Renovacare RCAR | FY2021 | N/A | -$4.5M | N/A | $9K | — |
| Q Biomed QBIO | FY2022 | $284K | -$2.1M | N/A | $15K | — |
Where Virpax Pharmaceuticals Inc Ranks
Frequently Asked Questions
What are Virpax Pharmaceuticals Inc's total assets?
Virpax Pharmaceuticals Inc (VRPX) had $1.6M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Virpax Pharmaceuticals Inc spend on research and development?
Virpax Pharmaceuticals Inc (VRPX) invested $5.8M in research and development during fiscal year 2024.
What is Virpax Pharmaceuticals Inc's current ratio?
Virpax Pharmaceuticals Inc (VRPX) had a current ratio of 0.63 as of fiscal year 2024, which is below 1.0, which may suggest potential liquidity concerns.
Why is Virpax Pharmaceuticals Inc's debt-to-equity ratio negative or not reported?
Virpax Pharmaceuticals Inc (VRPX) has negative shareholder equity of -$914K as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.